MedTrace Logo

Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis

NCT04462003 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-07-08

No results posted yet for this study

Summary

The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous (LMWH). It was hypothesised that Apixaban could be as effective as rivaroxiban and edoxaban in treatment of patients with acute DVT and active malignancy with a lower risk of bleeding especially in those with GIT cancer.

Conditions

  • Deep Vein Thrombosis
  • Malignancy

Interventions

DRUG

Apixaban

10 mg/12 h for 1 week followed by 5 mg/12 h

DRUG

Enoxaparin

1mg/Kg/sc/12h

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Mostafa E Mokadem · Faculty of Medicine, Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-03
Primary Completion
2020-07-02
Completion
2020-07-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462003 on ClinicalTrials.gov